Taiji Group (600129.SH) issued an announcement. Recently, the company's holding subsidiary Southwest Pharmaceutical Co., Ltd. (...
Zhitong Finance App News, Taiji Group (600129.SH) issued an announcement. Recently, Southwest Pharmaceutical Co., Ltd. (hereinafter: Southwest Pharmaceutical), a holding subsidiary of the company, received the “Supplementary Application Approval” for fluorouracil injection (10ml: 0.25g) from the State Drug Administration. Southwest Pharmaceutical's fluorouracil injection (10ml: 0.25g) passed the consistent evaluation of generic drug quality and efficacy.
Fluorouracil injections have a broad spectrum of antineoplastic effects. They are mainly used to treat gastrointestinal tumors, or to treat chorionic epithelial carcinoma with higher doses of fluorouracil. It is also commonly used to treat breast cancer, ovarian cancer, lung cancer, cervical cancer, bladder cancer, and skin cancer. Up to now, Southwest Pharmaceutical has invested a total of 8.4 million yuan in R&D expenses for this product (unaudited).